PAK1 and myxofibrosarcoma: Although PF3758309 is considered a pan-PAK inhibitor not targeting PAK1 alone 14, 33, this drug might indeed exert a notably specific repressive effect on PAK1-driven angiogenesis, an oncogenic attribute not redundantly phenocopied by PAK2-4, in myxofibrosarcomas at least.